Optic neuritis: Diagnosis, treatment and follow up;Optikusnevritt - Diagnose, behandling og oppfølging

Tidsskrift for den Norske Laegeforening

Volumn 125, Issue 4, 2005, Pages 425-428

  Midgard, Rune ^a,b   Seland, Johan H ^b   Hovdal, Harald ^c   Celius, Elisabeth Gulowsen ^d   Eriksen, Ketil ^d   Jensen, Ditlev ^e   Heger, Hilde ^d   Mellgren, Svein Ivar ^f   Wexler, Alexandra ^c   Beiske, Antonie Giæver ^g   Myhr, Kjell Morten ^a  

^a Nevrologisk Avdeling   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f Universitetssykehuset Nord Norge ^*  (Norway)

^g AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; METHYLPREDNISOLONE; PREDNISOLONE; GLUCOCORTICOID;

CORTICOSTEROID THERAPY; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; FOLLOW UP; HUMAN; MULTIPLE SCLEROSIS; OPTIC NERVE DISEASE; PRACTICE GUIDELINE; REVIEW; TREATMENT OUTCOME; VISION; ARTICLE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; RETRACTED ARTICLE; RISK FACTOR; VISUAL ACUITY;

DIAGNOSIS, DIFFERENTIAL; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; MAGNETIC RESONANCE IMAGING; METHYLPREDNISOLONE; MULTIPLE SCLEROSIS; OPTIC NEURITIS; PRACTICE GUIDELINES; RISK FACTORS; VISUAL ACUITY;

EID: 14244249331     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Anmarkrud N, Sletlnes ON. Uncomplicated retrobulbar neuritis and the development of multiple sclerosis. Acta Ophthalmol (Copenh) 1989; 67: 306-9.
2. Grønning M, Mellgren SI, Schive K. Optic neuritis in the two northernmost counties of Norway. A study of incidence and the prospect of later development of multiple sclerosis. Arctic Med Res 1989; 48: 117-21.
3. Jin YP, Pedro-Cuesta J, Söderström M et al. Incidence of optic neuritis in Stockholm, Sweden, 1990-1995, I. Age, sex, birth and ethnic-group related patterns. J Neural Sci 1998; 159: 107-14.
4. Kinnunen E. The incidence of optic neuritis and its prognosis for multiple sclerosis. Acta Neurol Scand 1983; 68: 371-7.
5. Rodriguez M, Siva A, Cross SA et al. Optic neuritis: a population-based study in Olmsted County, Minnesota. Neurology 1995; 45: 244-50.
6. Sandberg-Wollheim M, Bynke H, Cronqvist S et al. A long-term prospective study of optic neuritis: evaluation of risk factors. Ann Neurol 1990; 27: 386-93.
7. Trobe JD, Sieving PC, Guire KE et al. The impact of the optic neuritis treatment trial on the practices of ophthalmologists and neurologists. Ophthalmology 1999; 106: 2047-53.
8. Ghosh A, Kelly SP, Mathews J et al. Evaluation of the management of optic neuritis: audit on the neurological and ophthalmological practice in the north west of England. J Neurol Neurosurg Psychiatry 2002; 72: 119-21.
9. Jacobs LD, Beck RW, Simon JH et al. Intramuscular Interferon Beta-1 a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000; 343: 898-904.
10. Comi G, Filippi M, Barkhof F et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576-82.
11. Beck RW. Optic neuritis. I: Miller NR, Newman NJ, red. Walsh and Hoyt's clinical neuro-ophthalmology. 5. utg. Baltimore: Williams and Wilkins, 1998: 599-647.
12. Perkin GD, Rose FC. Optic neuritis and its differential diagnosis. Oxford: Oxford University Press, 1979.
13. Gronseth GS, Ashman EJ. Practice parameter: The usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 54: 1720-5.
14. Biousse V, Trichet C, Bloch-Michel E et al. Multiple sclerosis associated with uveitis in two large clinic-based series. Neurology 1999; 52: 179-81.
15. Optic Neuritis Study Group. The clinical profile of optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol 1991; 109: 1673-8.
16. Haarr M. Periphlebitis retinae ved sclerosis multiplex. En klinisk undersakelse. Doktoravhandling. Oslo: Øyeavdelingen, Rikshospitalet, 1951.
17. Lightman S, McDonald WI, Bird AC et al. Retinal venous sheathing in optic neuritis: its significance for the pathogenesis of multiple sclerosis. Brain 1987; 110: 405-14.
18. Engell T, Sellebjerg F, Jensen C. Changes in the retinal veins in acute optic neuritis. Acta Neurol Scand 1999; 100: 81-3.
19. Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis: experience of the optic neuritis treatment trial. Neurology 1997; 49: 1401-13.
20. Frederiksen JL, Serensen TL, Sellebjerg F. Residual symptoms and signs after untreated optic neuritis. A one-year follow-up. Acta Ophthalmol Scand 1997; 75: 544-7.
21. Slagsvold JE. Pulfrich pendulum phenomenon in t patients with a history of acute optic neuritis. Acta Ophthalmol 1978; 56: 817-26.
22. Hickman SJ, Dalton CM, Miller DH et al. Management of acute optic neuritis. Lancet 2002; 360: 1953-62.
23. Eggenberger ER. Inflammatory optic neuropathies. Ophthalmol Clin North Am 2001; 14: 73-82.
24. Lee AG, Lin DJ, Kaufman M et al. Atypical features prompting neuroimaging in acute optic neuropathy in adults. Can J Ophthalmol 2000; 35: 325-30.
25. Gass A, Moseley IF. The contribution of magnetic resonance imaging in the differential diagnosis of optic nerve damage. J Neurol Sci 2000; 172 (suppl 1): S17-22.
26. Carmody RF, Mafee MF, Goodwin JA et al. Orbital and optic pathway sarcoidosis: MR findings. AJNR Am J Neuroradiol 1994; 15: 775-83.
27. Acheson J. Optic nerve and chiasmal diseases. J Neurol 2000; 247: 587-96.
28. Holder GE. Pattern electroretinography (PERG) and an integrated approach to visual pathway diagnosis. Prog Ret Eye Res 2001; 20: 531-61.
29. Brusaferri F, Candelise L. Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol 2000; 247: 435-42.
30. Kaufman DI, Trobe JD, Eggenberger ER et al. Practice parameter: the role of corticosteroids in the management of acute monosymptomatic optic neuritis. Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2000; 54: 2039-44.
31. Wenning GK, Wietholter H, Schnauder G et al. Recovery of the hypothalamic-pituitary-adrenal axis from suppression by short-term, high-dose intravenous prednisolone therapy in patients with MS. Acta Neurol Scand 1994; 89: 270-73.
32. Morales DS, Siatkowski RM, Howard CW et al. Optic neuritis in children. J Pediatr Ophthalmol Strabismus 2000; 37: 254-9.
33. Kriss A, Francis DA, Cuendet F et al. Recovery after optic neuritis in childhood. J Neurol Neurosurg Psychiatry 1988; 51: 1253-8.
34. Brex PA, O'Riordan Jl, Miszkiel KA et al. Multisequence MRI in clinically isolated syndromes and the early development of MS. Neurology 1999; 53: 1184-90.
35. Brex PA, Ciccarelli O, O'Riordan JI et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002; 346: 158-64.
36. McDonald WI, Compston A, Edan G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-7.
37. Midgard R, Beiske AG, Celius EG et al. Nye diagnostiske kriterier ved multippel Sklerose. Tidsskr Nor Lægeforen 2003; 123: 1345-8.
38. Bakke SJ, Lilleås F, Smievoll AI et al. Bruk av MR i diagnostikk av multippel Sklerose. Tidsskr Nor Lægeforen 2003; 123: 1349-51.
39. Beck RW, Cleany PA, Trobe JD et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 1993; 329: 1764-9.
40. Dalton CM, Brex PA, Mizkiel KA et al. Spinal cord MRI in clinically isolated optic neuritis. J Neurol Neurosurg Psychiatry 2003; 74: 1577-80.
41. Bot JCJ, Barkhof F, Polman CH et al. Spinal cord abnormalities in recently diagnoses MS patients. Added value of spinal cord MRI examination. Neurology 2004; 62: 226-33.
42. Polman CH, Uitdehaag BNJ, Klok AM. Ocular comorbidity in multiple sclerosis. Lancet 2003; 361: 1230.